Candiada Albicans Prototype Experimental Candidate Vaccines

Authors

  • Ibrahim Mohamed Saeed Shnawa College of Biotechnology, University of QASIM, Babylon, Iraq and Hilla University College, Babylon, Iraq.

DOI:

https://doi.org/10.9734/bpi/mono/978-81-19217-14-4/CH15

Keywords:

Attenuated, cell, develop, experimental, killed, peptide, recombinant, vaccine

Abstract

Whole cell live attenuated, whole cell killed, pan-fungal, conjugate, antibody, and DNA vaccine experimental strategies have been laboratory developed for prevention and therapy of mucosal and systemic C. albicans in an experimental prime and challenge mice models. These models have shown immune efficacy of 60-100 %.Recombinant peptide vaccine strategies have shown 100% efficacy in laboratory development and pass to phase I human clinical trials in mucosal and disseminated candidiasis models.

Published

2023-04-22

How to Cite

Ibrahim Mohamed Saeed Shnawa. (2023). Candiada Albicans Prototype Experimental Candidate Vaccines. Vaccines and Vaccine Interference, 47–50. https://doi.org/10.9734/bpi/mono/978-81-19217-14-4/CH15

Issue

Vaccines and Vaccine Interference

Section

Contents